Page last updated: 2024-12-09
pyrrolopyrimidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pyrrolopyrimidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 577022 |
SCHEMBL ID | 63453 |
SCHEMBL ID | 7854 |
SCHEMBL ID | 22959928 |
MeSH ID | M0519940 |
Synonyms (25)
Synonym |
---|
272-50-4 |
pyrrolopyrimidine |
1,4,6-triazaindene |
5h-pyrrolo(3,2-d)pyrimidine |
5h-pyrrolo[3,2-d]pyrimidine |
FT-0650230 |
A818976 |
452-20-0 |
AKOS006326646 |
AM20090338 |
PB22262 |
SCHEMBL63453 |
KCTZOTUQSGYWLV-UHFFFAOYSA-N |
SCHEMBL7854 |
1h-pyrrolo[3,2-d]pyrimidine |
J-517588 |
mfcd09834826 |
CS-W022388 |
DS-10602 |
alpha-[1-(t-butylamino)ethyl]-2,5-dimethoxybenzylalcoholhydrochloride |
SCHEMBL22959928 |
SY097782 |
EN300-697544 |
DTXSID401346584 |
1,4,6-triaza-1h-indene |
Research Excerpts
Overview
Pyrrolopyrimidines are an important class of natural products. They have a broad spectrum of biological activities, including antibacterial, antifungal, antiviral, anticancer or anti-inflammatory.
Excerpt | Reference | Relevance |
---|---|---|
"Pyrrolopyrimidines are an important class of natural products with a broad spectrum of biological activities, including antibacterial, antifungal, antiviral, anticancer or anti-inflammatory. " | ( Identification of a Biosynthetic Gene Cluster Responsible for the Production of a New Pyrrolopyrimidine Natural Product-Huimycin. Luzhetskyy, A; Myronovskyi, M; Nadmid, S; Shuai, H, 2020) | 2.22 |
Pharmacokinetics
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Once weekly dosing brings greater patient compliance and more stable glycemic control." | ( Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool. Dou, W; Guo, J; Hu, W; Huang, H; Li, M; Ma, Y; Xie, H; Zeng, S; Zhao, N; Zhao, X; Zhou, Q; Zhou, Y, 2020) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (89)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (6.74) | 29.6817 |
2010's | 65 (73.03) | 24.3611 |
2020's | 18 (20.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 33.17
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.17) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (1.09%) | 5.53% |
Reviews | 5 (5.43%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 86 (93.48%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |